reVision Therapeutics
Developing treatment for Stargardt Disease which causes blindness in 32K people annually
- Stage Product In Development
- Industry Biotechnology
- Location New York, NY, USA
- Currency USD
- Founded October 2018
- Employees 6
- Incorporation Type C-corp
- Website revisiontx.com
Company Summary
reVision is developing a treatment for Stargardt disease, which causes blindness in 32K people each year and currently has no approved cure. reVision’s technology relies on an approved compound used as a non-active medium for intravenous drug delivery. Stargardt is an orphan disease and our product can qualify for accelerated approval: We anticipate to be in human clinical trials in 2020 and approved for marketing by the end of 2022.
Team
-
CFO
- As a banker led or participated in 44 financings that raised $767M for life sciences companies
- CFO of Sellas Life Sciences (Nasdaq: SLS); took the company public through a reverse merger and raised $10.7M in funding -
CEO
- 30 years' experience in life sciences, IP
- Novartis, Global Head of IP
- Baker Botts, Partner
- Adviser to startups in all stages throughout his career -
Janine PenmanHead of Stargardt Program
- Clinical development subject matter expert and operations strategist with 20 years of industry-side experience supporting biopharmaceutical asset development
- Biotherapeutics, Inc., SPR Biosciences, Parexel, Pfizer, Shire, AstraZeneca, ClinCon and Quintiles -
Co-founder, CSO
- Bioengineer with expertise in retinal biomechanics and corneal physiology; research scientist in basic mechanisms that could help to alleviate Dry Eye Disease and Diabetic Retinopathy
- Graduate of Cornell's entrepreneurship program and has held postdoctoral fellowships at Weill Cornell Medicine and the University of Leipzig, a PhD from the University of Leipzig, and Master's and Bachelor's (equivalent) from Politecnico di Milano -
Chaitanya BadweCo-founder, Business Development
- Consultant with ClearView Healthcare Partners, life sciences business development and operations
- Chaitanya is a graduate of Cornell's entrepreneurship program and has a PhD from Weill Cornell Graduate School of Medical Sciences, a Master's degree from The Johns Hopkins University, and a Bachelor's degree from the Institute of Chemical Technology, India
Advisors
-
Brian BrooksUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.